Astrid R.Spain


San Diego + 1.858.314.1167

Astrid Spain has more than 20 years of experience in global patent portfolio design and implementation, management, and enforcement in the life sciences, particularly in the areas of diagnostics, sequencing, antibody therapeutics, and liquid biopsy-related technologies. She frequently leads due diligences for transactions and financings involving life sciences companies and venture capital firms. Astrid participates in patent litigations as well as in inter partes review (IPR) proceedings.

Astrid has represented companies in many sectors of the life sciences and biotechnology industries, including start-up ventures and Fortune 500 companies. Astrid focuses on the shaping of global patent portfolios that achieve offensive and defensive business goals in view of competitive technologies and life cycle management. She frequently performs due diligence evaluations of patent portfolios and provides advice on validity and freedom-to-operate issues in connection with potential investments, licenses, and acquisitions.

Astrid has been repeatedly recognized by the Daily Journal as one of California's Top 100 intellectual property lawyers as well as one of California's Top 25 portfolio managers.


  • Sloan Kettering and Juno Therapeutics win over $1.1 billion after jury verdict and post-trial motions in patent dispute with Kite Pharma/Gilead involving CAR-T therapyOn behalf of patentee Sloan Kettering Institute and exclusive licensee Juno Therapeutics (a subsidiary of Celgene Corporation, a Bristol Myers Squibb company), Jones Day and co-counsel prevailed in a jury trial that spanned eight days and involved 22 witnesses, wherein the jury awarded our clients $752 million in compensation for the infringement of their patents by Kite Pharma, Inc. (a Gilead Sciences, Inc. company) through the making and selling of its infringing CAR-T therapy, YESCARTA®.
  • Wellbeing Genomics secures more than $1 million in damages in DNA test trade secret jury trial and successfully defends award on appealFollowing a two week trial, a jury in Austin, Texas returned a verdict in favor of Jones Day client Wellbeing Genomics Pty Ltd. in a trade secret case involving technology related to the use of individuals' genetic variations to determine risk in five skin health categories and to make recommendations of skin care product ingredients and treatments based on chemical compositions.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Kyowa Hakko Kirin and BioWa successfully enforce patent rights on antibody technologyJones Day, on behalf of Japanese life sciences company Kyowa Hakko Kirin Company, Limited ("KHK") and its wholly-owned U.S. subsidiary, BioWa, successfully settled a patent infringement suit over three of KHK's patents that underlie KHK's award-winning POTELLIGENT® technology capable of producing therapeutic antibodies with dramatically improved potency and efficacy.
  • Celgene acquires Juno Therapeutics for $9 billionOn behalf of Celgene Corporation, Jones Day conducted a large-scale intellectual property due diligence review and evaluation of matters related to its definitive merger agreement and acquisition of Juno Therapeutics for approximately $9 billion, including Juno’s technology related to CAR-T and TCR cellular immunotherapeutics for use in oncology and other indications.
  • Kyowa Hakko Kirin defeats competitors in Patent Trial and Appeal Board challenge of patents on antibody technologyOn October 23, 2017, the Patent Trial and Appeal Board ("PTAB") issued a trio of decisions, unanimously declining to institute inter partes review ("IPR") of three patents owned by a Japanese pharmaceutical company represented by Jones Day, Kyowa Hakko Kirin Co., Ltd.
  • Isis Pharmaceuticals builds patent portfolio for certain clinical development compoundsOn behalf of Isis Pharmaceuticals, Inc., Jones Day assisted with patent prosecution strategy and portfolio development concerning some of its clinical development compounds.
  • Speaking Engagements

    • March 3, 2020
      Association of Corporate Counsel Panel Discussion entitled, "Protecting Your Patents: Preparing for IPRs and Hatch-Waxman Litigation."
    • January 28, 2016
      2015 Patent Law Year in Review: (and a Look Ahead at 2016)
    • January 15, 2015
      2014 Patent Law Year in Review (and a Look Ahead at 2015)
    • January 15, 2014
      2013 Patent Law Year in Review (and a Look Ahead at 2014)
    • January 16, 2013
      2012 Patent Law Year in Review - and a Look Ahead at 2013
    • April 25, 2012
      Patent Strategies in the Aftermath of the Supreme Court's Decision in Mayo v. Prometheus
    • June 2009
      Emerging trends in IP Valuation and Risk Analysis
    • March 2009
      Patent Law Year in Review
    • June 2008
      Leveraging Intellectual Property to Accelerate Product & Technology Development
    • October 2007
      Leveraging Intellectual Property to Accelerate Product & Technology Development
    • January 2007
      Strafford Strategies for Patent Claim Construction, Live Interactive Teleconference
    • March 2003
      Strategic Research Institute- First International siRNA Conference
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.